Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316340PMC
http://dx.doi.org/10.15420/ecr.2023.18.PO20DOI Listing

Publication Analysis

Top Keywords

heart failure-exacerbating
4
failure-exacerbating medications
4
medications heart
4
heart failure
4
failure patients
4
patients tertiary
4
tertiary referral
4
referral centre
4
centre malaysia
4
heart
2

Similar Publications

Article Synopsis
  • Heart failure-exacerbating medications (HFEMs) are frequently used in patients with heart failure (HF) during emergency department (ED) visits, leading to potential preventable heart failure episodes.
  • An observational study analyzed 23,907 ED encounters from 2016 to 2020, revealing that 20% of these encounters involved the administration or prescription of HFEMs, with higher rates of administration in the ED compared to prescriptions at discharge.
  • The most commonly used HFEMs included nonsteroidal anti-inflammatory drugs (11%) and albuterol (7%), indicating a need for improved medication management for HF patients in the ED.
View Article and Find Full Text PDF

Insulin signaling is vital for regulating cellular metabolism, growth, and survival pathways, particularly in tissues such as adipose, skeletal muscle, liver, and brain. Its role in the heart, however, is less well-explored. The heart, requiring significant ATP to fuel its contractile machinery, relies on insulin signaling to manage myocardial substrate supply and directly affect cardiac muscle metabolism.

View Article and Find Full Text PDF

Cardiovascular (CV) diseases and tumors are best known for its high morbidity and mortality worldwide. There is a growing recognition of the association between CV diseases and tumorigenesis. In addition to CV damage caused by anti-tumor drugs and tumor-induced organ dysfunction, CV events themselves and their treatment may also have a role in promoting tumorigenesis.

View Article and Find Full Text PDF

Objectives: This study sought to describe the patterns of heart failure (HF)-exacerbating medications used among older adults hospitalized for HF and to examine determinants of HF-exacerbating medication use.

Background: HF-exacerbating medications can potentially contribute to adverse outcomes and could represent an important target for future strategies to improve post-hospitalization outcomes.

Methods: Medicare beneficiaries ≥65 years of age with an adjudicated HF hospitalization between 2003 and 2014 were derived from the geographically diverse REGARDS (Reasons for Geographic and Racial Difference in Stroke) cohort study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!